Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anakinra + methotrexate
- Development stage
- Unknown
- Lead developer
- Sobi
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of anakinra (a recombinant form of the endogenous interleukin-1 receptor antagonist) and methotrexate (a disease-modifying antirheumatic drug). This combination is primarily used for treating rheumatoid arthritis that has not responded adequately to methotrexate alone. The combination provides significantly greater clinical benefit than methotrexate monotherapy in reducing the severity of signs and symptoms of rheumatoid arthritis, improving physical function, and decreasing acute phase reactants.
02
Targets
DHFR (Dihydrofolate reductase)IL1R1 (Interleukin-1 Receptor Type 1)
Beyond the preview
Go deeper on anakinra + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anakinra + methotrexate.